Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Hepatitis C

Free Subscription Articles published in Transplantation Retrieve available abstracts of 50 articles: HTML format Text format

Single Articles

July 2018
1. SAGESHIMA J, Troppmann C, McVicar JP, Santhanakrishnan C, et al
   Impact of Willingness to Accept Hepatitis C Seropositive Kidneys Among Hepatitis C RNA-Positive Waitlisted Patients.
   Transplantation. 2018;102:1179-1187.
   PubMed     Text format     Abstract available
   
   
   June 2018
2. BOWRING MG, Kucirka LM, Massie AB, Ishaque T, et al
   Changes in utilization and discard of HCV-antibody positive deceased-donor kidneys in the era of direct-acting antiviral therapy.
   Transplantation. 2018 Jun 13. doi: 10.1097/TP.0000000000002323.
   PubMed     Text format     Abstract available
   
   
   May 2018
3. TUCCI A, Rizza S, Cocchis D, Martini S, et al
   Early and late hepatitis B reactivation following IFN- or DAA-based therapy of recurrent hepatitis C in anti-HBc-positive liver transplant recipients.
   Transplantation. 2018 May 2. doi: 10.1097/TP.0000000000002241.
   PubMed     Text format    
   
   
   January 2018
4. MCCAULEY M, Mussell A, Goldberg D, Sawinski D, et al
   Race, Risk, and Willingness of End-stage Renal Disease Patients Without Hepatitis C (HCV) to Accept an HCV-infected Kidney Transplant.
   Transplantation. 2018 Jan 18. doi: 10.1097/TP.0000000000002099.
   PubMed     Text format     Abstract available
   
   
   November 2017
5. TROTTER PB, Summers DM, Ushiro-Lumb I, Robb M, et al
   Use of organs from hepatitis C virus positive donors for uninfected recipients: a potential cost-effective approach to save lives?
   Transplantation. 2017 Nov 22. doi: 10.1097/TP.0000000000002033.
   PubMed     Text format     Abstract available
   
   
   
6. AGARWAL N, Davis RJ, Gracey DM, Wong G, et al
   Detection of Hepatitis C antibodies without viral transmission in Hepatitis C negative recipients receiving kidneys from Hepatitis C positive donors treated with Direct Acting Anti-Viral Therapy.
   Transplantation. 2017 Nov 22. doi: 10.1097/TP.0000000000002034.
   PubMed     Text format    
   
   
   
7. HOLSCHER CM, Durand CM, Desai NM
   Expanding the Use of Organs from Hepatitis C-Viremic Donors: The Evidence Continues to Build.
   Transplantation. 2017 Nov 22. doi: 10.1097/TP.0000000000002032.
   PubMed     Text format    
   
   
   October 2017
8. HEO NY, Mannalithara A, Kim D, Udompap P, et al
   Long-term Patient and Graft Survival of Kidney Transplant Recipients with Hepatitis C Virus Infection in the United States.
   Transplantation. 2017 Oct 3. doi: 10.1097/TP.0000000000001953.
   PubMed     Text format     Abstract available
   
   
   August 2017
9. ANTONINI TM, Coilly A, Rossignol E, Fougerou-Leurent C, et al
   Sofosbuvir-based Regimens in HIV/HCV Coinfected Patients after Liver Transplantation: Results from the ANRS CO23 CUPILT Study.
   Transplantation. 2017 Aug 24. doi: 10.1097/TP.0000000000001928.
   PubMed     Text format     Abstract available
   
   
   
10. CHOLANKERIL G, Li AA, Yoo ER, Ahmed A, et al
    Direct-Acting Antiviral Therapy and Improvement in Graft Survival of Hepatitis C Liver Transplant Recipients.
    Transplantation. 2017 Aug 24. doi: 10.1097/TP.0000000000001926.
    PubMed     Text format    
    
    
    
11. GARCIA CR, Acosta LF, Mei X, Berger J, et al
    Liver Transplantation for the Treatment of Complicated Iatrogenic Biliary Injuries: A National Review from the UNOS Dataset.
    Transplantation. 2017 Aug 22. doi: 10.1097/TP.0000000000001922.
    PubMed     Text format     Abstract available
    
    
    
12. ABAALKHAIL F, Elsiesy H, Elbeshbeshy H, Shawkat M, et al
    Treatment of Patients With Hepatitis C Virus infection (Genotype 4) With Ledipasvir-Sofosbuvir in the Liver Transplant Setting.
    Transplantation. 2017 Aug 9. doi: 10.1097/TP.0000000000001907.
    PubMed     Text format     Abstract available
    
    
    July 2017
13. PRUETT TL, Clark MA, Taranto SE
    Deceased Organ Donors and PHS Risk Identification: Impact on Organ Usage and Outcomes.
    Transplantation. 2017;101:1670-1678.
    PubMed     Text format     Abstract available
    
    
    
14. VOLK ML, Wilk AR, Wolfe C, Kaul DR, et al
    The "PHS Increased Risk" Label Is Associated With Nonutilization of Hundreds of Organs per Year.
    Transplantation. 2017;101:1666-1669.
    PubMed     Text format     Abstract available
    
    
    May 2017
15. SINGH N, Dies D, Samant H
    Hepatitis C-Positive Kidney Transplant Recipients-When Is The Best Time to Treat With Direct-Acting Antiviral Agents?
    Transplantation. 2017;101:e192.
    PubMed     Text format    
    
    
    
16. TERRAULT NA, Berenguer M, Strasser SI, Gadano A, et al
    International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients.
    Transplantation. 2017;101:956-967.
    PubMed     Text format    
    
    
    
17. TERRAULT NA, McCaughan GW, Curry MP, Gane E, et al
    International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates.
    Transplantation. 2017;101:945-955.
    PubMed     Text format    
    
    
    
18. TAPPER EB, Afdhal NH, Curry MP
    Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C.
    Transplantation. 2017;101:933-937.
    PubMed     Text format     Abstract available
    
    
    April 2017
19. MARTIN MT, Koppe S
    Elbasvir/Grazoprevir Use in Postliver Transplantation Patients on Hemodialysis.
    Transplantation. 2017 Apr 3. doi: 10.1097/TP.0000000000001758.
    PubMed     Text format     Abstract available
    
    
    March 2017
20. TERRAULT N, Berenguer M, Strasser S, Gadano A, et al
    International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT RECIPIENTS.
    Transplantation. 2017 Mar 1. doi: 10.1097/TP.0000000000001704.
    PubMed     Text format    
    
    
    
21. TERRAULT NA, McCaughan GW, Curry MP, Gane E, et al
    International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT CANDIDATES.
    Transplantation. 2017 Mar 1. doi: 10.1097/TP.0000000000001708.
    PubMed     Text format    
    
    
    
22. ARONSOHN A
    Timing is Everything: Managing Hepatitis C in Liver Transplant Candidates.
    Transplantation. 2017 Mar 1. doi: 10.1097/TP.0000000000001703.
    PubMed     Text format    
    
    
    February 2017
23. VERNA EC, Brown RS Jr
    HCV Antiviral Therapy In Liver Transplant Candidates and Recipients with Renal Insufficiency.
    Transplantation. 2017 Feb 16. doi: 10.1097/TP.0000000000001688.
    PubMed     Text format     Abstract available
    
    
    
24. SANTOS AH JR, Casey MJ, Xuerong W, Womer KL, et al
    Association of Baseline Viral Serology and Sirolimus Regimens With Kidney Transplant Outcomes: A 14-Year Registry-Based Cohort Study in the United States.
    Transplantation. 2017;101:377-386.
    PubMed     Text format     Abstract available
    
    
    January 2017
25. VINAIXA C, Strasser SI, Berenguer M
    DISEASE REVERSIBILITY IN PATIENTS WITH POSTHEPATITIS C CIRRHOSIS: IS THE POINT OF NO RETURN THE SAME BEFORE AND AFTER LIVER TRANSPLANTATION? A REVIEW.
    Transplantation. 2017 Jan 6. doi: 10.1097/TP.0000000000001633.
    PubMed     Text format     Abstract available
    
    
    
26. 
    Impact of Cytomegalovirus Infection on Severe Hepatitis C Recurrence in Patients Undergoing Liver Transplantation: Erratum.
    Transplantation. 2017;101:e40.
    PubMed     Text format    
    
    
    December 2016
27. DEBES JD, de Knegt RJ, Boonstra A
    The path to cancer, and back: Immune modulation during hepatitis C virus infection, progression to fibrosis and cancer, and unexpected roles of new antivirals.
    Transplantation. 2016 Dec 30. doi: 10.1097/TP.0000000000001623.
    PubMed     Text format     Abstract available
    
    
    
28. LUBETZKY M, Chun S, Joelson A, Coco M, et al
    Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients with Directly Acting Antiviral Agents.
    Transplantation. 2016 Dec 22. doi: 10.1097/TP.0000000000001618.
    PubMed     Text format     Abstract available
    
    
    
29. WERNER JM, Adenugba A, Protzer U
    Immune reconstitution following HCV clearance with direct antiviral agents: potential consequences for patients with HCC?
    Transplantation. 2016.
    PubMed     Text format     Abstract available
    
    
    
30. SALAZAR J, Saxena V, Kahn JG, Roberts JP, et al
    Cost-Effectiveness of Direct-Acting Anti-viral Treatment in Hepatitis C-infected Liver Transplant Candidates with Compensated Cirrhosis and Hepatocellular Carcinoma.
    Transplantation. 2016.
    PubMed     Text format     Abstract available
    
    
    
31. CARRILLO CF, Crespo G, de la Revilla J, Castells L, et al
    Successful continuation of HCV treatment following liver transplantation.
    Transplantation. 2016.
    PubMed     Text format     Abstract available
    
    
    
32. CROOME KP, Lee DD, Keaveny AP, Taner CB, et al
    Improving National Results in Liver Transplantation Using Grafts From Donation After Cardiac Death Donors.
    Transplantation. 2016;100:2640-2647.
    PubMed     Text format     Abstract available
    
    
    November 2016
33. BARBIER L, Cesaretti M, Dondero F, Cauchy F, et al
    Liver Transplantation With Older Donors: A Comparison With Younger Donors in a Context of Organ Shortage.
    Transplantation. 2016;100:2410-2415.
    PubMed     Text format     Abstract available
    
    
    September 2016
34. ELFEKI M, Abou Mrad R, Modaresi Esfeh J, Zein N, et al
    Sofosbuvir/Ledipasvir without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence after Liver Transplantation: Two-Center Experience.
    Transplantation. 2016.
    PubMed     Text format     Abstract available
    
    
    August 2016
35. EISENBERGER U, Guberina H, Willuweit K, Bienholz A, et al
    Successful treatment of chronic hepatitis C virus infection with sofosbuvir and ledipasvir in renal transplant recipients.
    Transplantation. 2016.
    PubMed     Text format     Abstract available
    
    
    
36. D S, N P, B A, Rd B, et al
    Use of HCV+ donors does not affect HCV clearance with directly acting antiviral therapy but shortens the wait time to kidney transplantation.
    Transplantation. 2016.
    PubMed     Text format     Abstract available
    
    
    
37. TAPPER EB, Hughes MS, Buti M, Dufour JF, et al
    The optimal timing of hepatitis C therapy in transplant eligible patients with Child B and C Cirrhosis: A Cost-Effectiveness Analysis.
    Transplantation. 2016.
    PubMed     Text format     Abstract available
    
    
    July 2016
38. SAWINSKI D, Lee DH, Doyle AM, Blumberg EA, et al
    Successful Posttransplant Treatment of Hepatitis C with Ledipasvir-Sofosbuvir in HIV+ Kidney Transplant Recipients.
    Transplantation. 2016.
    PubMed     Text format     Abstract available
    
    
    April 2016
39. BRAUN HJ, Dodge JL, Roll GR, Freise CE, et al
    Impact of Graft Selection on Donor and Recipient Outcomes After Living Donor Liver Transplantation.
    Transplantation. 2016.
    PubMed     Text format     Abstract available
    
    
    March 2016
40. FAISAL N, Bilodeau M, Aljudaibi B, Hirsch G, et al
    Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
    Transplantation. 2016.
    PubMed     Text format     Abstract available
    
    
    February 2016
41. WERNER JM, Vermehren J
    New HCV Therapies and Liver Transplantation.
    Transplantation. 2016;100:260-1.
    PubMed     Text format    
    
    
    December 2015
42. TANIMINE N, Tanaka Y, Abe T, Piao J, et al
    Functional Behavior of NKp46-Positive Intrahepatic Natural Killer Cells Against Hepatitis C Virus Reinfection After Liver Transplantation.
    Transplantation. 2015.
    PubMed     Text format     Abstract available
    
    
    
43. ABERG F, Nordin A, Toivonen L, Isoniemi H, et al
    Early Predictors of Long-term Outcomes of HCV-Negative Liver Transplant Recipients Having Survived the First Postoperative Year.
    Transplantation. 2015.
    PubMed     Text format     Abstract available
    
    
    October 2015
44. PARSIKIA A, Ortiz C, Ortiz J
    Response to Kidney Transplantation Threshold in Patients With Hepatitis C: A Decision Analysis Model.
    Transplantation. 2015;99:e165.
    PubMed     Text format    
    
    
    September 2015
45. CASTON JJ, Castells L, Varo E, Gomez MA, et al
    Impact of Cytomegalovirus Infection on Severe Hepatitis C Recurrence in Patients Undergoing Liver Transplantation.
    Transplantation. 2015.
    PubMed     Text format     Abstract available
    
    
    
46. UEDA Y, Uemoto S
    Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients.
    Transplantation. 2015.
    PubMed     Text format     Abstract available
    
    
    
47. PAPE E, Scala-Bertola J, Petitpain N, Jouzeau JY, et al
    Management of Tacrolimus-Telaprevir Drug-Drug Interaction in a Liver Transplant Patient With Hepatitis C Virus: Practical Considerations.
    Transplantation. 2015;99:e163-e164.
    PubMed     Text format    
    
    
    July 2015
48. SAWINSKI D, Bloom RD
    Novel Hepatitis C Treatment and the Impact on Kidney Transplantation.
    Transplantation. 2015.
    PubMed     Text format     Abstract available
    
    
    
49. LOCKE JE, Durand C, Reed RD, MacLennan PA, et al
    Long-Term Outcomes After Liver Transplantation Among Human Immunodeficiency Virus-Infected Recipients.
    Transplantation. 2015.
    PubMed     Text format     Abstract available
    
    
    June 2015
50. ASCHER NL
    Nancy L. Ascher, MD, PhD: Professor and Chair, Department of Surgery, UCSF; Past-President, ASTS; President-elect, The Transplantation Society.
    Transplantation. 2015;99:1106.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: